Xuan L, et al. - Sorafenib's impact on the outcomes of patients with acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3)–internal tandem duplication (ITD) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), was determined. In patients with FLT3-ITD AML, improved outcomes could be achieved with sorafenib before transplantation, sorafenib maintenance after transplantation, and also with their combined application.